NF-κB驱动的转录程序预示多发性骨髓瘤CAR-T持久缓解
配对样本分析显示NF-κB活性是T细胞适应性的内在标志,存在于CAR-T制备前的骨髓和外周血T细胞中;药理抑制NF-κB可体外消除CAR-T细胞毒性和细胞因子产生。
要点
- ide-cel产品中CD4 CAR-T细胞的NF-κB驱动转录程序与持久缓解相关。
- 该程序包含促生存、趋化因子信号和CAR转基因高表达,独立于基线特征。
- NF-κB活性是CAR-T制备前即存在的T细胞适应性标志。
核心结论
- ide-cel产品中NF-κB活性是影响CAR-T功能的信号轴,并代表CAR-T制备前即存在的T细胞适应性全局标志。
研究设计与样本
- 分析配对单采和肿瘤微环境样本,并行体外药理抑制NF-κB的功能验证。
主要发现
- CD4 CAR-T细胞中NF-κB信号、促生存回路、 tonic/趋化因子信号和CAR转基因高表达与持久缓解相关。
- 这些特征与延长的无进展生存和总生存相关, irrespective of基线临床特征。
- elevated NF-κB activity是T细胞适应性的内在标志,表现为中央记忆表型且缺乏检查点受体表达。
- 这些特征在CAR-T制备前的骨髓来源和外周血T细胞中即已显现。
- 药理抑制NF-κB在体外消除了CAR-T细胞毒性和细胞因子产生。
临床怎么用
- NF-κB活性可作为筛选持久缓解患者的潜在标志,并指导CAR-T制备优化策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idecabtagene vicleucel (ide-cel) induces deep responses in relapsed/refractory multiple myeloma, yet more than half of patients relapse within 1 year. The intrinsic features of chimeric antigen receptor T-cell (CAR-T) products that distinguish durable from nondurable responders are poorly defined, particularly at single-cell resolution, and defining drivers of durable response is critical to guide patient counseling and to inform strategies for optimizing CAR-T manufacturing and efficacy. To address this need, 40 ide-cel infusion products (184 398 cells) were profiled using single-cell RNA sequencing. These analyses revealed that a transcriptional program in CD4 CAR-T cells that led to durable responses is characterized by NF-κB signaling, prosurvival circuits, tonic/chemokine signaling, and elevated CAR transgene expression. These features were associated with prolonged progression-free and overall survival irrespective of baseline clinical characteristics. Further, analyses of paired apheresis and tumor microenvironment samples showed that elevated NF-κB activity is an intrinsic hallmark of T-cell fitness that is characterized by a central memory phenotype and the lack of checkpoint receptor expression, and that these features were manifest in marrow-derived and peripheral blood T cells before CAR-T manufacturing. Finally, validating functional relevance, the pharmacologic inhibition of NF-κB abrogated CAR-T cytotoxicity and cytokine production in vitro. Our results support that NF-κB in the ide-cel product marks a signaling axis affecting CAR-T function and that NF-κB activity represents a global marker of T-cell fitness present before CAR-T manufacture.
引用
- Noble JD, Peixoto BC, Menges MA, et al. Product-intrinsic NF-κB-driven transcriptional programs connote durability of CAR-T response in multiple myeloma. Blood. 2026. PMID: 42275255. doi:10.1182/blood.2025031843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。